Motzer et al. have recently identified seven ccRCC subtypes with specific angiogenesis, immune, metabolic, stromal, and cell-cycle profiles showing differential clinical outcomes to VEGF blockade alone or in combination with anti-PD-L1 [14]. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.